Project Report for Tablet Manufacturing
Pharmaceutical formulations are transformed into compressed solid dosage forms during the tablet manufacturing process using procedures like weighing, blending, granulation, drying, lubrication, compression, coating, inspection, and packing. Investment is mostly dependent on product category, batch size, and manufacturing scope. The company needs regulated production settings, qualified quality systems, suitable pharmaceutical equipment, and regulatory compliance. Get a Completely Custom Bankable Project Report by Sharda Associates—Rs. 2,999 onwards, delivered in 24-48 hrs, backed by 45,500+ CA-certified reports
Get free Sample
Is There a Recent Regulatory Change You Need to Know About Before Planning This Business?
Yes. One of the most important recent changes for a tablet manufacturing project is the revised Schedule M Good Manufacturing Practice (GMP) requirements, notified in December 2023. The revised framework significantly strengthens requirements for pharmaceutical premises, plant, equipment, quality systems, documentation, utilities, and manufacturing controls, bringing Indian GMP requirements closer to international standards.
This matters directly to a new tablet manufacturing project because the facility should be designed around the revised GMP framework from the beginning, rather than treating compliance as something to upgrade after production starts. Requirements can affect HVAC systems, water and other utilities, equipment qualification, quality-control laboratories, documentation, personnel, sanitation, and validation. The CDSCO also issued provisions in 2025 concerning extensions for compliance with revised Schedule M, showing that the transition has been an active regulatory issue rather than an old guideline.
There is also continuing regulatory activity around pharmacovigilance and drug-product oversight. CDSCO’s current circulars include implementation of pharmacovigilance requirements under Schedule M, while regulatory actions concerning unapproved fixed-dose combinations demonstrate that product selection itself needs regulatory review before it is included in a manufacturing plan.
What Does It Actually Cost to Set Up a Schedule M-Compliant Tablet Plant?
This is genuinely capital-intensive, and it’s worth understanding realistically rather than assuming it’s a light MSME entry point. A documented reference figure for a Schedule M-compliant formulations plant with three compression machines put the cost at roughly ₹9.18 crore, covering the compression machines themselves, associated manufacturing and quality equipment, and factory/office construction. This specific figure is from 2012 and needs meaningful upward adjustment for current costs and the additional requirements under Revised Schedule M — treat it as a historical reference point illustrating the genuine capital scale of this business, not a current quotation. Build your actual project cost from current machinery and construction quotations.
Is There a Lower-Investment Way Into This Industry, or Does It Require Building Your Own Full Plant?
There’s a genuinely common and legitimate alternative worth knowing about: third-party (contract) manufacturing and PCD (Propaganda Cum Distribution) franchise models let you enter the pharmaceutical business without building your own Schedule M-compliant facility from scratch. Under these models, an already-licensed, WHO-GMP-certified manufacturer produces tablets to your specifications or brand, while you focus on marketing, distribution, and brand-building. This is how many smaller pharma businesses genuinely start in India, building market presence and cash flow before — if ever — committing to the capital required for owned manufacturing capacity.
What Certifications Does a Serious Buyer or Distributor Actually Check?
Beyond the baseline legal requirement of a CDSCO-approved manufacturing license and Schedule M compliance, WHO-GMP certification and ISO 9001:2015 are close to a market credibility baseline that distributors, franchise partners, and export buyers specifically look for. Buyers also expect a manufacturer to readily provide Batch Manufacturing Records (BMR) and Batch Packing Records (BPR), a Certificate of Analysis (COA) for every batch, and stability data supporting shelf-life claims — this documentation discipline is what actually separates a manufacturer serious distributors want to work with from one they avoid.
What Does the Manufacturing Process Actually Involve?
The process moves through raw material (API and excipient) receipt and quality testing, granulation (wet or dry, depending on the formulation), compression (forming the tablet using the compression machines that dominate your core capital cost), coating (where the formulation requires it, for taste-masking, controlled release, or moisture protection), and packaging, with quality control testing — including dissolution, hardness, and content uniformity testing — built into multiple stages of the process, not just as a final check.
What Government Support Actually Applies to This Industry Specifically?
This is worth knowing because it’s genuinely more developed than generic MSME support. The PLI (Production Linked Incentive) Scheme for Pharmaceuticals carries a ₹15,000 crore outlay, and a separate PLI scheme for Key Starting Materials, Drug Intermediates, and APIs (covering Bulk Drug Parks) carries a further ₹6,940 crore. More directly relevant for a smaller manufacturer specifically upgrading to Revised Schedule M compliance, the Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), under the Department of Pharmaceuticals, provides subsidies and soft loans specifically supporting MSME facility upgrades to the new standard — worth exploring directly if your project involves bringing an existing or new facility up to Revised Schedule M compliance.
What Licenses Does This Business Actually Need?
- Drug Manufacturing License from the State (or Central) Drug Licensing Authority under the Drugs and Cosmetics Act
- Revised Schedule M GMP compliance, with your applicable phased deadline depending on your turnover category
- WHO-GMP certification — not always a strict domestic legal requirement, but a practical necessity for serious distributor, franchise, and export relationships
- ISO 9001:2015 certification
- Qualified technical staff appointment (pharmacist/technical personnel), required before license application
- Pollution Control Board Consent, given pharmaceutical manufacturing effluent considerations
What Documents Does a Bank Actually Ask For?
- Aadhaar and PAN of promoters
- Drug Manufacturing License, or application status with facility readiness clearly documented
- Machinery quotations (compression, granulation, coating, and packaging equipment) matched to your target formulation types
- A project report specifying your business model (own manufacturing vs. third-party/PCD entry) and Revised Schedule M compliance timeline
- Land/facility documents suited to Schedule M-compliant construction
- Bank statements for the last 12 months, and financials for existing entities
Frequently Asked Questions
Revised Schedule M significantly strengthens India's pharmaceutical GMP requirements. A new manufacturing unit should generally design its facility, equipment, utilities, documentation, quality systems, and manufacturing processes around the currently applicable requirements rather than planning around older standards.
Yes. Third-party or contract manufacturing and PCD-based business models can allow entrepreneurs to enter the pharmaceutical market without establishing their own manufacturing facility. The manufacturing is carried out through an appropriately licensed facility while the entrepreneur focuses on product marketing and distribution.
WHO-GMP certification should not be treated as a universal substitute for or additional statutory requirement beyond the applicable Indian licensing and GMP framework. However, recognised GMP certification can be commercially valuable for distributor relationships, institutional buyers, and export markets.
Important pharmaceutical documentation can include Batch Manufacturing Records (BMR), Batch Packing Records (BPR), Certificates of Analysis (COA), specifications, validation records, and stability data supporting applicable shelf-life claims. Documentation requirements should be established according to the product and regulatory framework.
Yes. The Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS) was introduced to support eligible pharmaceutical MSMEs with technology and GMP-related upgrades. Eligibility, assistance structure, and current scheme conditions should be verified from the Department of Pharmaceuticals before including the support in project financing.
It can be considerably more capital-intensive because a compliant pharmaceutical facility requires specialised production equipment, controlled environmental conditions, utilities, quality-control laboratories, validation, documentation systems, and other GMP infrastructure. A third-party manufacturing model can substantially reduce the initial capital requirement.
Yes. Pharmaceutical manufacturing is a regulated activity, and the appropriate drug manufacturing licence and approvals must be obtained before commercial production. The exact licensing pathway depends on the product category, dosage form, premises, and applicable regulatory authority.
Potentially, but each formulation must be assessed for manufacturing compatibility, regulatory approval, equipment requirements, contamination-control measures, batch size, and quality testing. The proposed product portfolio should therefore be finalised before determining the plant layout and machinery requirements.